This study supports a central role of PDE10A in progressive pulmonary vascular remodeling and suggests that inhibition of PDE10A is a novel therapeutic approach against pulmonary vascular remodeling for the treatment of PAH. This evidence concerns the gene PDE10A and pulmonary arterial hypertension.